Disease · MONDO_0005097

squamous cell lung carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. squamous cell lung carcinoma. Diseases, record MONDO_0005097. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005097

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: squamous cell lung carcinoma; Open Targets
Open Targets ID: MONDO_0005097; Open Targets
Other names: epidermoid cell carcinoma of lung, epidermoid cell carcinoma of the lung, epidermoid cell lung carcinoma, lung squamous cell carcinoma, squamous cell carcinoma of lung, squamous cell carcinoma of the lung, squamous cell lung cancer; Open Targets
Disease Ontology: DOID:3907; Disease Ontology
NCI Thesaurus: C3493; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 15 of its 79 drugs, from ClinicalTrials.gov; Open Targets

Drugs79

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	12	12	9	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
AFATINIB	CHEMBL1173655	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 79

See all 79 drugs

Targets97

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Unknown	https://conductscience.org/library/genes/2908	Drugs and targets
PDCD1	Programmed cell death protein 1	7	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
EGFR	Epidermal growth factor receptor	6	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 97

See all 97 targets

Trials67

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02154490	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer		1,864	2023-01-31	Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	DOCETAXEL, DURVALUMAB, ERLOTINIB HYDROCHLORIDE, IPILIMUMAB, NIVOLUMAB, PALBOCICLIB, RILOTUMUMAB, TALAZOPARIB, TASELISIB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01523587	LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy	Phase 3	795	2014-11-21	Carcinoma, Non-Small-Cell Lung	AFATINIB, ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03594747	A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer	Phase 3	360	2023-10-17	Non-Small Cell Lung Cancer	CARBOPLATIN, PACLITAXEL, TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02785952	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	Phase 3	275	2022-01-11	Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01803282	Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors	Phase 1	236	2020-05-04	Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer	ANDECALIXIMAB, BEVACIZUMAB, CARBOPLATIN, FLUOROURACIL, GEMCITABINE, IRINOTECAN, LEUCOVORIN CALCIUM, OXALIPLATIN, PACLITAXEL, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT04552535	A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung		200	2021-07-08	Squamous Non-small Cell Lung Cancer	AFATINIB	Its record names the disease	ClinicalTrials.gov
NCT02766335	Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	Phase 2/3	116	2021-12-30	Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	DURVALUMAB	Its record names the disease	ClinicalTrials.gov
NCT01652469	Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.	Phase 3	81	2019-08-08	Carcinoma, Non-Small-Cell Lung	DOCETAXEL, ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03373760	Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer	Phase 2	67	2022-01-21	Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02785939	Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer	Phase 2/3	53	2021-05-27	CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	DOCETAXEL, PALBOCICLIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 67

See all 67 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Afatinib vs Erlotinib: Number of Participants With Disease Control According to RECIST 1.1	201 of 398	157 of 397	795	NCT01523587	Trial comparisons
Afatinib vs Erlotinib: Number of Participants With Objective Response According to RECIST 1.1	22 of 398	11 of 397	795	NCT01523587	Trial comparisons
Afatinib vs Erlotinib: deaths from any cause	77 of 392	71 of 395	787	NCT01523587	Trial comparisons
Afatinib vs Erlotinib: serious adverse events	174 of 392	175 of 395	787	NCT01523587	Trial comparisons
Nivolumab + Ipilimumab vs Nivolumab: deaths from any cause	92 of 125	105 of 127	252	NCT02785952	Trial comparisons
Nivolumab + Ipilimumab vs Nivolumab: serious adverse events	78 of 124	58 of 123	247	NCT02785952	Trial comparisons
Second-line Afatinib Treatment Group vs Second-line Chemotherapy Treatment Group: Number of Patients With Severe Immune-related Adverse Events (irAEs) of Specific Interest During Second-line Treatment	6 of 99	0 of 101	200	NCT04552535	Trial comparisons
Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): deaths from any cause	58 of 68	26 of 30	98	NCT02766335	Trial comparisons
Arm I & Arm III (Initial Treatment and Retreatment With MEDI4736) vs Arm II (Docetaxel - Closed to Accrual 4/2015): serious adverse events	27 of 68	3 of 30	98	NCT02766335	Trial comparisons
A: Erlotinib vs B: Docetaxel: deaths from any cause	7 of 38	3 of 41	79	NCT01652469	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials40

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29691300	RESULT	1	PubMed
25961845	RESULT	1	PubMed
24128713	RESULT	1	PubMed
23554766	RESULT	1	PubMed
22960745	RESULT	1	PubMed
21277552	RESULT	1	PubMed
19410716	RESULT	1	PubMed
17167137	RESULT	1	PubMed
16425523	RESULT	1	PubMed
16043828	RESULT	1	PubMed

1 to 10 of 40

See all 40 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005097

GET https://conductscience.org/api/diseases/v1/MONDO_0005097/drugs?page=2

API reference For AI assistants